Clinicopathological and preoperative molecular findings among prospectively assayed 17 IPMNs and 2 MCNs with advanced neoplasia
| Patient | Gender | Age (years) | Primary clinical symptom | Cyst size (cm) | Ductal dilatation | Mural nodule | Malignant cytopathology* | KRAS mutation (MAF) | GNAS mutation (MAF) | VHL alteration | TP53 alteration (MAF) | PIK3CA mutation (MAF) | PTEN deletion (MAF) | Diagnostic pathology |
| 1 | Woman | 77 | Asymptomatic | 4.6 | Absent | Present | Present | p.G12D (40%) | p.R201C (48%) | Absent | Homozygous deletion† | Absent | Homozygous deletion† | AdenoCA arising in an IPMN (pT1bN0) |
| 2 | Man | 72 | Jaundice | 4.7 | Absent | Present | Present | p.G12V (29%); p.G12D (7%) | Absent | Absent | p.R175H (38%); p.G199L (18%) | p.H1047Y (28%) | Absent | AdenoCA arising in an IPMN (pT1cN0) |
| 3 | Man | 51 | Pancreatitis | 3.0 | Present | Present | Absent | p.G12D (40%) | p.R201C (53%) | Absent | Homozygous deletion† | Absent | Absent | AdenoCA arising in an IPMN (pT1bN0) |
| 4 | Man | 82 | Asymptomatic | 3.7 | Present | Absent | Absent | p.G12D (19%) | p.R201H (15%) | Absent | p.R110L (16%) | Absent | Absent | AdenoCA arising in an IPMN (pT1bN0) |
| 5 | Man | 61 | Jaundice | 5.2 | Present | Present | Present | p.G12D (21%) | Absent | Absent | p.R175H (21%) | Absent | Absent | AdenoCA arising in an IPMN (pT1cN0) |
| 6 | Man | 48 | Asymptomatic | 0.9 | Absent | Present | Absent | p.G12V (15%) | Absent | Absent | p.R248W (16%) | Absent | Absent | AdenoCA arising in an IPMN (pT1aN0) |
| 7 | Man | 46 | Abdominal pain | 3.7 | Absent | Absent | Absent | p.G12V (33%) | Absent | Absent | Absent | p.E545K (29%) | Absent | AdenoCA arising in an IPMN (pT1cN0) |
| 8 | Woman | 62 | Asymptomatic | 2.7 | Absent | Present | Absent | p.G12R (11%) | Absent | Absent | p.R273H (19%) | Absent | Absent | AdenoCA arising in an IPMN (pT1aN0) |
| 9 | Woman | 56 | Pancreatitis | 2.3 | Absent | Absent | Absent | p.G12R (18%) | Absent | Absent | p.R273H (23%) | Absent | Absent | AdenoCA arising in an IPMN (pT1bN0) |
| 10 | Man | 77 | Asymptomatic | 3.0 | Absent | Absent | Absent | Absent | p.R201H (51%) | Absent | Absent | p.E545K (50%) | Absent | AdenoCA arising in an IPMN (pT1aN0) |
| 11 | Woman | 58 | Abdominal pain | 5.0 | Absent | Absent | Present | p.G12V (7%) | Absent | Absent | Absent | p.Y1021C (5%) | Absent | AdenoCA arising in an IPMN (pT1bN0) |
| 12 | Woman | 72 | Asymptomatic | 2.0 | Present | Absent | Absent | p.G12V (41%) | Absent | Absent | p.D259Y (43%) | Absent | Absent | AdenoCA arising in an IPMN (pT1aN0) |
| 13 | Man | 74 | Abdominal pain | 2.7 | Absent | Absent | Present | p.G12R (26%) | Absent | Absent | p.R273H (29%) | Absent | Absent | AdenoCA arising in an IPMN (pT1bN0) |
| 14 | Man | 67 | Weight loss | 3.5 | Present | Absent | Absent | Absent | p.R201C (30%) | Absent | p.R181C (34%) | Absent | Absent | IPMN with high-grade dysplasia |
| 15 | Man | 72 | Asymptomatic | 1.5 | Present | Absent | Absent | Absent | p.R201C (39%) | Absent | p.R248W (42%) | Absent | Absent | IPMN with high-grade dysplasia |
| 16 | Man | 67 | Abdominal pain | 2.8 | Present | Absent | Absent | p.G12R (45%) | p.R201C (92%) | Absent | Absent | Absent | Absent | IPMN with high-grade dysplasia |
| 17 | Man | 72 | Asymptomatic | 3.0 | Present | Absent | Present | p.G12D (41%) | p.R201H (88%) | Absent | Absent | Absent | Absent | IPMN with high-grade dysplasia |
| 18 | Woman | 34 | Abdominal pain | 11 | Absent | Absent | Absent | p.G12D (15%) | Absent | Absent | Absent | Absent | Absent | MCN with high-grade dysplasia |
| 19 | Woman | 83 | Abdominal pain | 9.8 | Absent | Absent | Absent | p.G12R (22%) | Absent | Absent | Absent | Absent | Absent | MCN with high-grade dysplasia |
*Malignant cytopathology was defined as at least suspicious for adenocarcinoma.
†Homozygous deletion is based on low sequencing coverage of amplicons for the gene of interest.
AdenoCA, adenocarcinoma; IPMN, intraductal papillary mucinous neoplasm; MAF, mutant allelic frequency; MCN, mucinous cystic neoplasm.